Anavex Life Sciences Corporation
AVXL
Market Cap$921.16M
Close$
$1.58
85.3% downside
Current Fair Value
85.3% downsideOvervalued by 85.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $921.16 Million |
|---|---|
| Enterprise Value | $813.22 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.52 |
| Beta | 0.67 |
| Outstanding Shares | 85,074,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -25.54 |
|---|---|
| PEG | 25.54 |
| Price to Sales | - |
| Price to Book Ratio | 10.79 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -14.31 |
| Enterprise Value to Net Income | -23 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Anavex Life Sciences Corporation
CEO: Christopher Missling Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, ...